Paper34799993
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
Wang SY and 10 others. Thorac Cancer, 2022. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors. Papers, record 34799993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34799993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma of Lung | Major topic |
| Lung Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Aged | |
| Chemoradiotherapy | |
| ErbB Receptors | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Mutation | |
| Progression-Free Survival | |
| Retrospective Studies |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18378568 | Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18378568 | PubMed |
| 2 | 28881918 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28881918 | PubMed |
| 3 | 30926356 | Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer. | Clin Lung Cancer | 2019 | https://conductscience.org/library/papers/30926356 | PubMed |
| 4 | 33539970 | Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. | J Thorac Oncol | 2021 | https://conductscience.org/library/papers/33539970 | PubMed |
| 5 | 29151359 | Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29151359 | PubMed |
| 6 | 30152040 | Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR. | Thorac Cancer | 2018 | https://conductscience.org/library/papers/30152040 | PubMed |
| 7 | 30059262 | CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). | J Clin Oncol | 2018 | https://conductscience.org/library/papers/30059262 | PubMed |
| 8 | 23945383 | Lung cancer and prognosis in taiwan: a population-based cancer registry. | J Thorac Oncol | 2013 | https://conductscience.org/library/papers/23945383 | PubMed |
| 9 | 25051378 | Verification of wild-type EGFR status in non-small cell lung carcinomas using a mutant-enriched PCR on selected cases. | J Mol Diagn | 2014 | https://conductscience.org/library/papers/25051378 | PubMed |
| 10 | 28885561 | Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer. | Cancers (Basel) | 2017 | https://conductscience.org/library/papers/28885561 | PubMed |
| 11 | 29864379 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29864379 | PubMed |
| 12 | 28885881 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28885881 | PubMed |
| 13 | 28693247 | Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28693247 | PubMed |
| 14 | 36119641 | Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study. | Ther Adv Med Oncol | 2022 | https://conductscience.org/library/papers/36119641 | PubMed |
| 15 | 30150014 | Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. | Lancet Respir Med | 2018 | https://conductscience.org/library/papers/30150014 | PubMed |
| 16 | 30153097 | CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/30153097 | PubMed |
| 17 | 23211219 | The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy. | Am J Clin Oncol | 2014 | https://conductscience.org/library/papers/23211219 | PubMed |
| 18 | 31751012 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31751012 | PubMed |
| 19 | 21904576 | Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. | Ther Adv Med Oncol | 2011 | https://conductscience.org/library/papers/21904576 | PubMed |
| 20 | 26324372 | Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26324372 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42434745 | Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42434745 | PubMed |
| 41659261 | Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/41659261 | PubMed |
| 35806042 | State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35806042 | PubMed |
| 34799993 | Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors. | Thorac Cancer | 2022 | https://conductscience.org/library/papers/34799993 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34799993
GET https://conductscience.org/api/papers/v1/34799993/references?page=2